藥事未核准檢驗(LDT:Laboratory Developed Test)的技術與市場
Laboratory-Developed Testing: Technologies and Markets
|出版日期||內容資訊||英文 104 Pages
|藥事未核准檢驗(LDT:Laboratory Developed Test)的技術與市場 Laboratory-Developed Testing: Technologies and Markets|
|出版日期: 2015年01月01日||內容資訊: 英文 104 Pages||
美國的藥事未核准檢驗(LDT:Laboratory Developed Test)市場2013年記錄為81億美元，2014年為97億美元的市場規模。從2014年到2019年，預計以12.7％的年複合成長率發展，2019年成長到177億美元的規模。
本報告提供藥事未核准檢驗(LDT:Laboratory Developed Test)的技術和市場相關調查、LDT的技術及適應症種類與概要、LDT的利用的理由和FDA核准完畢檢驗的差異、市場規模的變化與預測、主要技術及專利詳細內容、相關法律、R&D趨勢、對市場成長的各種影響因素，產業課題等分析，主要經營者簡介等彙整資料。
The laboratory-developed test market within the U.S. was valued at $8.1 billion in 2013 and $9.7 billion in 2014. The market is expected to reach roughly $17.7 billion in 2019, a compound annual growth rate (CAGR) of 12.7% from 2014 to 2019.
This report will focus on companies that rely on laboratory-developed testing for at least 10% of their revenue. This is meant to avoid focusing on companies and laboratories that only occasionally offer laboratory-developed tests to deal with unique patient needs. This report will also focus on suppliers of the analyte-specific reagents used within these laboratory-developed tests, as their contract manufacturing is a key to the successful development of these tests. While various technologies will be highlighted with relation to their use in laboratory-developed testing, we will not explore the markets for these different technologies in depth.
Todd Graham is a licensed medical technologist in New York State with a strong background in assay development and clinical diagnostics. He has worked as a bench-level technologist for Quest Diagnostics and for hospital laboratories throughout the New York metropolitan area. He has also developed laboratory testing that is currently marketed in the United States. Todd works as an analyst for BCC Research and as a consultant to biotechnology and pharmaceutical firms on scientific and quality control matters.